Longlong Xie

941 total citations
27 papers, 465 citations indexed

About

Longlong Xie is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Longlong Xie has authored 27 papers receiving a total of 465 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Immunology. Recurrent topics in Longlong Xie's work include Autoimmune and Inflammatory Disorders Research (6 papers), Epigenetics and DNA Methylation (5 papers) and Parvovirus B19 Infection Studies (5 papers). Longlong Xie is often cited by papers focused on Autoimmune and Inflammatory Disorders Research (6 papers), Epigenetics and DNA Methylation (5 papers) and Parvovirus B19 Infection Studies (5 papers). Longlong Xie collaborates with scholars based in China, United States and Saudi Arabia. Longlong Xie's co-authors include Ya Cao, Ann M. Bode, Yueshuo Li, Min Tang, Feng Shi, Xiangjian Luo, Jianmin Hu, Lin Zhao, Weihua Liao and Wei‐Zhong Wu and has published in prestigious journals such as Scientific Reports, Frontiers in Immunology and Signal Transduction and Targeted Therapy.

In The Last Decade

Longlong Xie

22 papers receiving 462 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Longlong Xie China 12 264 145 119 94 76 27 465
Lixin Fu China 11 226 0.9× 174 1.2× 112 0.9× 171 1.8× 61 0.8× 39 536
Dianshan Ke China 14 277 1.0× 130 0.9× 102 0.9× 94 1.0× 91 1.2× 24 449
Zi‐Xun Yan China 10 242 0.9× 140 1.0× 101 0.8× 64 0.7× 76 1.0× 18 411
Hongde Li China 13 277 1.0× 212 1.5× 130 1.1× 106 1.1× 103 1.4× 14 556
Ju Ma China 13 297 1.1× 101 0.7× 189 1.6× 53 0.6× 55 0.7× 19 487
Liping Fan China 10 243 0.9× 89 0.6× 127 1.1× 75 0.8× 20 0.3× 34 407
Chithra D. Palani United States 13 317 1.2× 111 0.8× 41 0.3× 68 0.7× 54 0.7× 21 598
Huan Ning United States 11 204 0.8× 126 0.9× 94 0.8× 263 2.8× 38 0.5× 14 512
Xiwen Dong China 14 182 0.7× 107 0.7× 61 0.5× 134 1.4× 24 0.3× 19 469
Denis Đermadi United States 8 242 0.9× 214 1.5× 70 0.6× 149 1.6× 47 0.6× 15 534

Countries citing papers authored by Longlong Xie

Since Specialization
Citations

This map shows the geographic impact of Longlong Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Longlong Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Longlong Xie more than expected).

Fields of papers citing papers by Longlong Xie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Longlong Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Longlong Xie. The network helps show where Longlong Xie may publish in the future.

Co-authorship network of co-authors of Longlong Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Longlong Xie. A scholar is included among the top collaborators of Longlong Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Longlong Xie. Longlong Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Zan, Zitong Zhao, Longlong Xie, et al.. (2025). Proteomic analysis reveals chromatin remodeling as a potential therapeutical target in neuroblastoma. Journal of Translational Medicine. 23(1). 234–234. 11 indexed citations
2.
Zeng, Xiaohui, Ting Luo, Xiao Li, et al.. (2025). Active EBV infection in children: associations between DNA load, infection status, immune status, and disease severity. Virology Journal. 22(1). 113–113.
3.
Xie, Longlong, Xiaoli Li, Lin Zhao, et al.. (2024). CircMETTL3-156aa reshapes the glycolytic metabolism of macrophages to promote M1 polarization and induce cytokine storms in sHLH. Cell Death Discovery. 10(1). 431–431. 3 indexed citations
4.
Li, Yueshuo, Longlong Xie, Feng Shi, et al.. (2024). CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma. Cell Death and Disease. 15(1). 95–95. 7 indexed citations
5.
Xie, Longlong, et al.. (2024). Health‐Related Quality of Life Among Discharged Patients With Hemophagocytic Lymphohistiocytosis: A Follow‐Up Study. Pediatric Blood & Cancer. 72(2). e31431–e31431.
6.
Li, Xun, Xiao Li, Longlong Xie, et al.. (2024). Pre-diagnostic trajectory of pediatric hemophagocytic lymphohistiocytosis: observations from hematological and hepatic parameters. Annals of Hematology. 103(12). 5145–5155. 1 indexed citations
7.
8.
Li, Xun, Zhenghui Xiao, Ting Luo, et al.. (2023). A Three-Step Screening Procedure for Early Identification of Children at High Risk of Hemophagocytic Lymphohistiocytosis. Journal of Clinical Immunology. 43(5). 989–998. 3 indexed citations
9.
Yu, Bo, et al.. (2023). Classification method for failure modes of RC columns based on class-imbalanced datasets. Structures. 48. 694–705. 13 indexed citations
10.
Li, Xun, Zhenghui Xiao, Ting Luo, et al.. (2022). Development of a screening score for Hemophagocytic Lymphohistiocytosis among pediatric patients with acute infection of Epstein-Barr virus. Frontiers in Immunology. 13. 981251–981251. 5 indexed citations
11.
Li, Yueshuo, Feng Shi, Jianmin Hu, et al.. (2021). Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication. npj Precision Oncology. 5(1). 14–14. 14 indexed citations
12.
Zhao, Lin, Xiangying Deng, Yueshuo Li, et al.. (2021). Conformational change of adenine nucleotide translocase‐1 mediates cisplatin resistance induced by EBV‐LMP1. EMBO Molecular Medicine. 13(12). e14072–e14072. 15 indexed citations
13.
Cao, Ya, Longlong Xie, Feng Shi, et al.. (2021). Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study. Signal Transduction and Targeted Therapy. 6(1). 15–15. 74 indexed citations
14.
Xie, Longlong, et al.. (2021). Mitochondria-Shaping Proteins and Chemotherapy. Frontiers in Oncology. 11. 769036–769036. 11 indexed citations
15.
Shi, Feng, Jiangjiang Li, Min Tang, et al.. (2020). Wild-type IDH2 contributes to Epstein–Barr virus-dependent metabolic alterations and tumorigenesis. Molecular Metabolism. 36. 100966–100966. 23 indexed citations
16.
Hu, Jianmin, Yueshuo Li, Hongde Li, et al.. (2020). Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy. Theranostics. 10(26). 11921–11937. 38 indexed citations
17.
Xie, Longlong, Feng Shi, Yueshuo Li, et al.. (2020). Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. Signal Transduction and Targeted Therapy. 5(1). 56–56. 89 indexed citations
18.
Du, Qianqian, Zheqiong Tan, Feng Shi, et al.. (2019). PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation. Cancer Science. 110(6). 2050–2062. 82 indexed citations
19.
Shi, Feng, Min Zhou, Shang Li, et al.. (2019). EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter. Theranostics. 9(9). 2424–2438. 49 indexed citations
20.
Xie, Longlong, et al.. (2011). The design and realization of ground control system for multi-UAV. Chinese Control Conference. 3809–3813. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lixin Fu Breakdown of academic impact, for papers by Dianshan Ke Breakdown of academic impact, for papers by Zi‐Xun Yan Breakdown of academic impact, for papers by Hongde Li Breakdown of academic impact, for papers by Ju Ma Breakdown of academic impact, for papers by Liping Fan Breakdown of academic impact, for papers by Chithra D. Palani Breakdown of academic impact, for papers by Huan Ning Breakdown of academic impact, for papers by Xiwen Dong Breakdown of academic impact, for papers by Denis Đermadi
Rankless by CCL
2026